Should You Buy Quoin Pharmaceuticals Ltd - ADR (QNRX) Stock After it Has Gained 52.56% in a Week?

Overall market sentiment has been high on Quoin Pharmaceuticals Ltd - ADR (QNRX) stock lately. QNRX receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Quoin Pharmaceuticals Ltd - ADR has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on QNRX!

See Full QNRX Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With QNRX Stock Today?

Quoin Pharmaceuticals Ltd - ADR (QNRX) stock is trading at $2.38 as of 3:31 PM on Friday, Feb 3, a decline of -$0.15, or -5.93% from the previous closing price of $2.53. The stock has traded between $2.23 and $2.44 so far today. Volume today is less active than usual. So far 401,278 shares have traded compared to average volume of 735,885 shares.

More About Quoin Pharmaceuticals Ltd - ADR

Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others. Click Here to get the full Stock Report for Quoin Pharmaceuticals Ltd - ADR stock.